(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Without the use of MC planning, target structures were substantially underdosed. Local failures were associated with PTVmicro undercoverage, which suggests that delivering a therapeutic dose to this expanded microscopic disease target volume is beneficial. MC dosimetry is preferable for lung SBRT, while the PB algorithm is adequate for predicting pulmonary toxicity.

Colbert A. Parker, BS, Roger Ove, MD, PhD, Madhu B. Chilikuri, PhD, Suzanne M. Russo, MD;University of South Alabama School of Medicine; Mitchell Cancer Institute

BACKGROUND: Promising results have been obtained using stereotactic body radiosurgery (SBRT) for early-stage lung cancer. The calculation of dose in pulmonary parenchyma can be inaccurate.

MATERIALS AND METHODS: We retrospectively analyzed 47 cases treated over a 2-year period with CyberKnife SBRT, planned with the standard pencil beam (PB) algorithm. Cases were a mixture of early-stage lung cancer and oligometastatic cases. The median prescribed dose was 50 Gy in four or five fractions. We compared the planned dose with the dose actually delivered, as estimated with Monte Carlo (MC) dosimetry to the 1% level. We correlated the dosimetric deficiencies with recurrences, using deformable registration to determine the dose delivered to the site of recurrence.

RESULTS: With a median follow-up of 2 years, the local control at 1 year was 90%, declining to 70% at 2 years. The total number of local recurrences was 10, and 8 of these patients died with progressive disease. Two recurrences occurred synchronously with metastases, and two recurrences were in palliative cases treated to lower doses with tight margins, and disease was never cleared locally. MC calculations showed that the mean dose delivered to the planning target volume (PTV), averaged over all cases, was 7% lower than planned. Most cases were planned with an expansion on the PTV (PTVmicro = GTV + 8-mm expansion in lung + 3 mm), representing a region at risk for microscopic extension, and were intended to receive a minimum dose of 80% of the prescription dose. MC calculations showed that the minimum dose to this structure, averaged over all cases, was 47% lower than the intended dose. For cases that recurred, the mean dose to the PTVmicro was 8% lower than intended, while it was only 2% lower for those whose disease was controlled. There were no other significant differences in target coverage between patients with local control and local recurrence. The PB algorithm and MC estimates for pulmonary exposure were assessed, recording the V5, V10, and V20 for the ipsilateral and total lung volumes. These estimates roughly agreed for the two algorithms, with the MC results almost universally lower than PB by an absolute difference of 1% to 3% on average.

CONCLUSIONS: Without the use of MC planning, target structures were substantially underdosed. Local failures were associated with PTVmicro undercoverage, which suggests that delivering a therapeutic dose to this expanded microscopic disease target volume is beneficial. MC dosimetry is preferable for lung SBRT, while the PB algorithm is adequate for predicting pulmonary toxicity.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.
James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
Related Content